Last 12 months
Inside the activity.
5 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2021 Filed Aug 6, 2021 21:43 UTC |
Phanstiel S. LouiseDirector
|
Exercise / conversionCommon Stock | 30,000 | $21.29 | $638,700.00 |
DisclosureSEC source: 0001471518-21-000002 · edgardoc.xml · nonDerivative · entry 3 Phanstiel S. Louise · CIK 0001471518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 21:43 UTC |
Phanstiel S. LouiseDirector
|
SaleCommon Stock | 47,881 | $35.04 | $1,677,740.66 |
DisclosureSEC source: 0001471518-21-000002 · edgardoc.xml · nonDerivative · entry 2 Phanstiel S. Louise · CIK 0001471518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,646 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.49 to $35.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 21:43 UTC |
Phanstiel S. LouiseDirector
|
Exercise / conversionCommon Stock | 30,000 | $25.39 | $761,700.00 |
DisclosureSEC source: 0001471518-21-000002 · edgardoc.xml · nonDerivative · entry 1 Phanstiel S. Louise · CIK 0001471518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,775 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 18 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,225 Underlying: Common Stock · 11,775 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 38,225 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 17 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 38,225 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 11,775 | $35.57 | $418,855.59 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 12 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.57 to $35.58, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 11,775 | $27.07 | $318,749.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 11 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 38,225 | $35.24 | $1,347,171.32 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 10 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.09 to $35.51, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 38,225 | $27.07 | $1,034,750.75 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:23 UTC |
Riggsbee Richard BryanChief Financial Officer
|
SaleCommon Stock | 14,983 | $35.14 | $526,475.65 |
DisclosureSEC source: 0001621899-21-000006 · edgardoc.xml · nonDerivative · entry 1 Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,942 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.30, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,775 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 16 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,225 Underlying: Common Stock · 1,775 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,225 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 15 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,225 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 14 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,830 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,170 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 13 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,170 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 4,170 | $34.00 | $141,780.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,170 | $23.98 | $99,996.60 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 27,830 | $34.00 | $946,220.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 27,830 | $23.98 | $667,363.40 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 1,775 | $35.07 | $62,249.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,775 | $27.07 | $48,049.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 16,225 | $33.99 | $551,487.75 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 16,225 | $26.49 | $429,800.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:11 UTC |
LANGER DENNISDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $25.39 | $0.00 |
DisclosureSEC source: 0001274225-21-000004 · edgardoc.xml · derivative · entry 3 LANGER DENNIS · CIK 0001274225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:11 UTC |
LANGER DENNISDirector
|
SaleCommon Stock | 30,000 | $34.75 | $1,042,500.00 |
DisclosureSEC source: 0001274225-21-000004 · edgardoc.xml · nonDerivative · entry 2 LANGER DENNIS · CIK 0001274225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,527 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:11 UTC |
LANGER DENNISDirector
|
Exercise / conversionCommon Stock | 30,000 | $25.39 | $761,700.00 |
DisclosureSEC source: 0001274225-21-000004 · edgardoc.xml · nonDerivative · entry 1 LANGER DENNIS · CIK 0001274225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 12 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,225 Underlying: Common Stock · 40,000 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,295 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 11 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,225 Underlying: Common Stock · 3,295 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 40,000 | $33.74 | $1,349,756.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.49 to $33.96, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 40,000 | $26.49 | $1,059,600.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 3,295 | $33.69 | $111,011.52 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.205 to $33.95, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,295 | $26.49 | $87,284.55 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,295 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 10 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,520 Underlying: Common Stock · 13,295 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 36,705 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,815 Underlying: Common Stock · 36,705 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 13,295 | $33.55 | $446,075.17 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 13,295 | $26.49 | $352,184.55 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 36,705 | $33.55 | $1,231,430.73 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 36,705 | $26.49 | $972,315.45 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,603 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · derivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,520 Underlying: Common Stock · 5,603 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 26,705 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · derivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,123 Underlying: Common Stock · 26,705 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,692 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · derivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,692 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 17,692 | $32.47 | $574,459.24 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 17,692 | $19.47 | $344,463.24 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 5,603 | $32.29 | $180,920.87 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,603 | $26.49 | $148,423.47 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 26,705 | $32.79 | $875,656.95 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 26,705 | $26.49 | $707,415.45 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,424 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · derivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,828 Underlying: Common Stock · 30,424 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,884 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · derivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,884 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
SaleCommon Stock | 1,884 | $31.99 | $60,269.16 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC |
LANCHBURY JERRY SChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,884 | $26.49 | $49,907.16 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.